Data from Phase 3 Trial demonstrated improvement in time to relapse, the primary efficacy endpoint, for patients receiving once-monthly aripiprazole IM depot formulation compared to placebo Results ...
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
On Wednesday, 19 November 2025, at the Jefferies London Healthcare Conference 2025, Viking Therapeutics (NASDAQ:VKTX) presented a comprehensive update on its clinical programs. The company showcased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback